美多芭联合普拉克索对帕金森病患者血浆miR-124 miR-137和非运动症状的影响

doi:10.3969/j.issn.1006-6233.2020.08.008

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (1211 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effects of madopar combined with pramipexole on plasma microRNA -124(miR-124), microRNA -137(miR-137) and non-motor symptoms in patients with Parkinson's disease. Methods: 82 patients with Parkinson's disease who were treated in our hospital from July 2017 to April 2019 were randomly divided into control group and research group, 41 cases in each. The control group was treated with madopar, The research group was treated with madopar and pramipexole. The clinical effects of the two groups were observed and compared. The Parkinson's disease score scale (UPDRS), plasma miR-124 and miR-137 levels, improvement of non-motor symptoms and drug side effects were recorded and compared. Results: 3 months after treatment, the total effective rate of the research group was higher than that of the control group (P<0.05). One month and three months after treatment, the UPDRS scores of the two groups decreased, and the research group was lower than the control group. The UPDRS scores of the two groups were statistically different concerning different treatment methods and time (P<0.05). One month and three months after treatment, the plasma miR-124 in the two groups increased, and the research group was higher than the control group. the plasma miR-137 in the two groups decreased, and the research group was lower than the control group. the plasma miR-124 and miR-137 in the two groups were statistically different in different treatment methods and time (P<0.05). The rates of depression, anxiety and insomnia in the study group were lower than those in the control group (P<0.05). there was no statistical difference in the incidence rates of cognitive impairment, somnolence, constipation and hypotension between the two groups (P>0.05). There was no statistical difference in the total incidence of side effects between the two groups (P>0.05). Conclusion: Madopar combined with pramipexole can improve the curative effect of Parkinson's disease, regulate the expression of miR-124 and miR-137 in plasma, and improve non-motor symptoms.

Key words： Parkinson's disease Madopar Pramipexole MicroRNA-124 MicroRNA-137 Non-motor symptoms

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jing
	ZHANG Zhuo
	LI Xue

Cite this article:

WANG Jing,ZHANG Zhuo,LI Xue. Effects of Madopar Combined with Pramipexole on Plasma MicroRNA -124, MicroRNA -137 and Non-Motor Symptoms in Patients with Parkinson's Disease[J]. HeBei Med, 2020, 26(8): 1264-1268.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.008 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1264

[1] Godoi BB, Amorim GD, Quiroga DG, et al. Parkinson's disease and wearable devices, new perspectives for a public health issue: an integrative literature review[J]. Rev Assoc Med Bras (1992), 2019, 65(11):1413~1420.
[2] 陈敏.美多芭联合盐酸普拉克索治疗帕金森病非运动症状的临床效果[J].广西医学, 2019, 41(14):1784~1786, 1791.
[3] Behbahanipour M, Peymani M, Salari M, et al. Expression profiling of blood microRNAs 885, 361 and 17 in the patients with the parkinson's disease: integrating interaction data to uncover the possible triggering age-related mechanisms[J]. Sci Rep, 2019, 9(1):13759.
[4] Corvol JC, Mariani LL. Therapeutic and pharmacologic perspectives in Parkinson's disease[J]. Rev Prat, 2018, 68(5):515~519.
[5] Geibl FF, Henrich MT, Oertel WH. Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease[J].Neural Transm (Vienna), 2019, 126(4):377~396.
[6] Mohamed D, Hegazy MA, Elshahed MS, et al. Novel contribution to the simultaneous monitoring of pramipexole dihydrochloride monohydrate and levodopa as co-administered drugs in human plasma utilizing UPLC-MS/MS[J]. Eur Mass Spectrom (Chichester), 2018, 24(5):397~407.
[7] 尤汉生, 毛秀琴, 石俊, 等.美多芭联合普拉克索对老年帕金森病患者非运动症状的疗效分析[J].国际精神病学杂志, 2017, 44(4):649~651, 663.
[8] Schulz J, Takousis P, Wohlers I, et al. Meta-analyses identify differentially expressed micrornas in Parkinson's disease[J]. Ann Neurol, 2019 , 85(6):835~851.
[9] Yao L, Zhu Z, Wu J, et al. MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease[J]. Faseb, 2019, 33(7):8648~8665.
[10] 李淑华, 陈海波.帕金森病非运动症状研究进展及临床意义[J].中华神经科杂志, 2017, 50(1):71~74.
[11] Escalona R1, 2, Fawcett J1. Pramipexole in treatment resistant-depression, possible role of inflammatory cytokines[J]. Neuropsychopharmacology, 2017, 42(1):363.